

## BCAL DIAGNOSTICS – MARKET UPDATE

- **BCAL executes Product Development Agreement with IZON Science Limited (IZON)**
- **Expanding clinical study centres to all Australian states**
- **Recruitment of skilled scientists to accelerate development**
- **USA market entry discussions progressing**

Breast cancer screening and diagnostic company BCAL Diagnostics (ASX:BDX, 'BCAL' or the 'Company') is pleased to provide the following market update following its listing on the ASX on 21 July 2021. BCAL's focus is on the development of a blood-based test for diagnosis of breast cancer. Blood samples from large cohorts of breast cancer patients have been used to establish the test. Samples from a wider range of patients are now being examined, leading into formal clinical trials preparatory to registration of the test for clinical use.

### Product Development Agreement – IZON Science Limited (IZON)

BCAL has recently executed a Product Development Agreement with IZON. IZON will work with BCAL in the further development of the test. The agreement involves developing a bespoke kit, using IZON equipment and components, to accelerate the time for processing clinical samples and providing a format that can be processed rapidly and effectively by pathology laboratories.

### Expanding clinical study centres to all Australian states

BCAL, in collaboration with GenesisCare Clinical CRO, is expanding clinical study centres to all states of Australia. Additional agreements are under review and will enable BCAL to maintain the pace of development, notwithstanding the closure of a number of breast cancer screening centres due to COVID-19.

### Recruitment of skilled scientists to accelerate development

BCAL has recently recruited two highly skilled scientists in support of its product development, with experience in lipidomics, mass spectrometry and data analytics. Dr Cheka Kehelpannala has over 7 years' experience in lipidomics and analytical chemistry in Australia and Internationally.

Dr Mark David will relocate from the Imperial College London, which is a world leader in research, diagnosis and treatment of diseases. Dr David has over 17 years' experience in analytical chemistry, metabolomics/lipidomics and mass spectrometry.

### USA market entry discussions progressing

BCAL is working on accelerating its market entry into the USA and is in discussion with potential partners who can provide BCAL with scientific development, technical support on product development, and commercial input to market entry in relation to billing and reimbursement assistance.

Executive Chair Jayne Shaw commented: "BCAL, following its ASX listing and successful capital raise, is making excellent progress on the road to development of a non-invasive, cost effective, blood based diagnostic test to detect breast cancer.

*Our strengthened teams in research, clinical studies and regulatory affairs now have a clear roadmap and resources to develop this product to meet the growing global demand for breast cancer diagnostics."*

This ASX announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

## Investor & Media Enquiries

Matthew Wright  
NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

## About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 91% specificity and 87% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with global integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>